The US Food and Drug Administration is waiving premarket notification requirements for coagulation systems that can help health care providers monitor COVID-19 patients at risk of blood clots.
On 14 January, the agency published an emergency guidance that allows the devices, which are used to measure viscoelastic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?